NCT03540836View on ClinicalTrials.gov

A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 24, 2018

Primary Completion Date

July 16, 2018

Study Completion Date

July 25, 2018

Conditions
Healthy
Interventions
DRUG

Relacorilant (3x100 mg softgel capsules)

A single relacorilant 300mg dose (3x100 mg softgel capsules) will be given once on Day 1 of one of three treatment periods.

DRUG

Relacorilant (3x100 mg hard-shell capsules)

A single relacorilant 300mg dose (3x100 mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.

DRUG

Relacorilant (6x50mg hard-shell capsules)

A single relacorilant 300mg dose (6x50mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.

Trial Locations (1)

85283

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY